The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. - Luke JJ; Patel MR; Blumenschein GR; Hamilton E; Chmielowski B; Ulahannan SV; Connolly RM; Santa-Maria CA; Wang J; Bahadur SW; Weickhardt A; Asch AS; et al. (Nature medicine, 2023)